Use of amisulpride as an anti-emetic
View Patent ↗Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
1. A method for the prevention and/or treatment of nausea and/or vomiting that is induced by chemotherapy or radiation wherein said method comprises administering, to a subject in need of such prevention and/or treatment, amisulpride at a dose of 1-40 mg in combination with another anti-emetic drug, wherein the subject is also administered an emetogenic chemotherapeutic agent or the subject receives radiation therapy.
2. The method according to claim 1 , wherein the subject is further administered another emetogenic agent.
3. The method according to claim 2 , wherein the subject has cancer.
4. The method according to claim 1 , wherein the chemotherapeutic emetogenic agent is cisplatin.
5. The method according to claim 2 , wherein said another emetogenic agent is an opiate.
6. The method according to claim 2 , wherein said another emetogenic agent is morphine.
7. The method according to claim 1 , wherein the amisulpride is administered by intravenous injection.
8. The method according to claim 1 , wherein the amisulpride is administered by intramuscular injection.
9. The method according to claim 1 , wherein the amisulpride is administered by subcutaneous injection.
10. The method according to claim 1 , wherein the amisulpride is administered by rectal administration.
11. The method according to claim 1 , wherein the amisulpride is administered by intranasal administration.
12. The method according to claim 1 , wherein the amisulpride is administered by buccal administration.
13. The method according to claim 1 , wherein the amisulpride is administered by oral, transdermal, sublingual or inhaled administration.
14. The method according to claim 1 , wherein the subject is a human.
15. The method according to claim 1 , wherein the amisulpride is in the form of an acceptable pharmaceutical salt.
16. The method according to claim 1 , wherein the another anti-emetic drug is a 5HT3 antagonist.
17. The method according to claim 16 , wherein the 5HT3 antagonist is ondansetron.
18. The method according to claim 1 , wherein the subject receives radiation therapy.
19. The method according to claim 2 , wherein amisulpride is administered simultaneously or sequentially with the emetogenic chemotherapeutic agent.
20. The method according to claim 2 , wherein amisulpride is administered before or after the administration of the emetogenic chemotherapeutic agent.
21. The method according claim 1 , wherein the amisulpride is administered at a dose of 2.5 mg to 20 mg.
22. The method according to claim 1 , wherein the amisulpride is administered at a dose of 5 to 35 mg.
23. The method according claim 1 , wherein the amisulpride is administered once or twice a day.
24. A method for the prevention and/or treatment of nausea and/or vomiting wherein said method comprises administering, to a subject in need of such prevention and/or treatment, amisulpride at a dose of 1-40 mg in combination with another anti-emetic drug, wherein the subject is also administered an emetogenic agent that is an opiate.